Tue 2/25/2020 04:40 ET
DJIA27960.80995.403.56%TELCO189.521.840.97%GOLD1652.2524.291.47%Shanghai3013.0518.080.60%
S&P 5003225.90108.073.35%BANKS480.4116.333.40%OIL51.360.070.14%BITCOIN9599.5248.000.50%
NASDAQ9221.28342.113.71%PHARM602.9814.532.41%US/EU1.090.000.00%Futures3238.8812.630.39%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - AEterna Zentaris - AEZS   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add AEZS
  
From: efbailey (Rep: 1756)Date: 01/17/2018 08:02
Forum: AEterna Zentaris - Msg #2642Thread #673982824 (Rec: 0)
lic agreement for commercialization of Macrilen will receive an upfront cash payment of US$24,000,000 from Strongbridge, and, for as long as Macrilen™ (macimorelin) is patent-protected, Aeterna Zentaris will be entitled to a 15% royalty on net sales up to US$75,000,000 and an 18% royalty on net sales above US$75,000,000. Following the end of patent protection in United States or Canada for Macrilen™ (macimorelin), Aeterna Zentaris will be entitled to a 5% royalty on net sales in that country. In addition, Aeterna Zentaris will also receive one-time payments from Strongbridge following the first achievement of the following commercial milestone events:

US$4,000,000 on achieving US$25,000,000 annual net sales,
US$10,000,000 on achieving US$50,000,000 annual net sales,
US$20,000,000 on achieving US$100,000,000 annual net sales,
US$40,000,000 on achieving US$200,000,000 annual net sales, and
US$100,000,000 on achieving US$500,000,000 annual net sales.
Upon approval by the U.S. Food and Drug Administration (“FDA”) of a pediatric indication for Macrilen™ (macimorelin), Aeterna Zentaris will receive a one-time milestone payment of US$5,000,000 from Strongbridge.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser efbailey: Reward | Watch | IgnoreAEZS: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add AEZS
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.